KU-0063794

카탈로그 번호S1226 배치:S122605

인쇄

기술 자료

화학식

C25H31N5O4

분자량 465.54 CAS 번호 938440-64-3
용해도 (25°C)* 시험관 내(In vitro) DMSO 20 mg/mL (42.96 mM)
Water Insoluble
Ethanol Insoluble
생체 내(In Vivo) (개별적으로 순서대로 용매를 제품에 첨가하십시오.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
30%PEG400 0.5%Tween80 5%propylene glycol

Selleck 연구소에서 검증했습니다. 이 제형에 대한 조정이 필요한 경우 맞춤형 테스트를 위해 당사 영업팀에 문의하십시오.

30.000mg/ml (64.44mM) Taking the 1 mL working solution as an example, add 300 μL of 100 mg/ml clarified PEG400 stock solution to 5 μL of Tween80, mix evenly to clarify it; add 50 μL Propylene glycol to the above system, mix evenly to clarify it; then continue to add 645 μL ddH2O to adjust the volume. to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml은 약간 용해되거나 불용해됨을 의미합니다.
* Selleck은 모든 화합물의 용해도를 자체적으로 테스트하며, 실제 용해도는 게시된 값과 약간 다를 수 있습니다. 이는 정상적인 현상이며, 약간의 배치 간 변동으로 인해 발생합니다.
* 실온 배송 (안정성 테스트 결과 이 제품은 냉각 조치 없이 배송될 수 있음을 보여줍니다.)

원액 준비

생물학적 활성

설명 KU-0063794는 무세포 분석에서 ~10 nM의 IC50 값을 가지며 PI3K에 영향을 미치지 않는, mTORC1 및 mTORC2에 대한 강력하고 매우 특이적인 이중 mTOR 억제제입니다.
표적
mTORC1
(Cell-free assay)
mTORC2
(Cell-free assay)
~10 nM ~10 nM
시험관 내(In vitro)

Compared with the mTOR inhibitor PP242, KU-0063794 exhibits higher specificity for mTOR, as being inactive against PI3Ks or 76 other kinases. In HEK-293 cells, this compound at 30 nM is sufficient to rapidly ablate S6K1 activity by blocking the phosphorylation of the hydrophobic motif (Thr389) and subsequently the phosphorylation of the T-loop residue (Thr229). In case of IGF1 stimulation of serum-starved HEK-293 cells, 300 nM of this compound is needed to inhibit the S6K1 activity by ~90%. This chemical at 100-300 nM also completely inhibits the amino-acid-induced phosphorylation of S6K1 and S6 protein. Similar to S6K1, it inhibits the phosphorylation of mTORC1 at Ser2448 and mTORC2 at Ser2481 in a dose-dependent and time-dependent manner. In the presence of serum or following IGF1 stimulation, this compound induces a dose-dependent inhibition of the activity and phosphorylation of Akt at Ser473 and unexpected Thr308 as well as the phosphorylation of the Akt substrates PRAS40 at Thr246, GSK3α/GSK3β at Ser21/Ser9 and Foxo-1/3a at Thr24/Thr32. This compound but not rapamycin inhibits SGK1 activity and Ser422 phosphorylation as well as its physiological substrate NDGR1 in a dose-dependent manner, to the same extent as S6K1 and Akt phosphorylation, whereas it dose not inhibit phorbol ester induced ERK or RSK phosphorylation and RSK activation. Compared with rapamycin, this chemical exhibits more significant potency to induce the complete dephosphorylation of 4E-BP1 at Thr37, Thr46 and Ser65. It inhibits cell growth of both wild-type and mLST8-deficient MEFs and induces a G1 cell cycle arrest, more significantly than rapamycin.

생체 내(In Vivo)

Ku0063794 inhibits tumor growth and mTOR signaling in a preclinical renal cell carcinoma model. However, this compound was not more effective in the animal study. A possible explanation for lack of greater activity in vivo for this chemical.

프로토콜 (참조)

키나아제 분석:

[1]

  • mTOR 복합체 키나아제 분석

    HEK-293 세포를 Hepes 용해 완충액으로 즉시 용해합니다. 용해물(1-4 mg)을 사전 면역 IgG에 결합된 5-20 μL의 Protein G-Sepharose와 배양하여 전처리합니다. 그런 다음 용해물 추출물을 5-20 μg의 anti-Rictor 또는 anti-Raptor 항체 또는 사전 면역 IgG와 결합된 5-20 μL의 Protein G-Sepharose와 배양합니다. 모든 항체는 Protein G-Sepharose에 공유 결합되어 있습니다. 면역 침강은 진동 플랫폼에서 4 °C로 1시간 동안 수행합니다. 면역 침강물을 Hepes 용해 완충액으로 4회 세척한 후, Hepes 키나아제 완충액으로 2회 세척합니다. S6K1 인산화에 사용되는 Raptor 면역 침강물의 경우, 초기 두 번의 세척 단계에서 최적의 키나아제 활성을 보장하기 위해 완충액에 0.5 M NaCl을 포함합니다. GST-Akt1은 PI-103(1 μM, 1시간)으로 처리된 혈청 결핍 HEK-293 세포에서 분리합니다. GST-S6K1은 rapamycin(0.1 μM, 1시간)으로 처리된 혈청 결핍 HEK-293 세포에서 정제합니다. mTOR 반응은 다양한 농도의 KU-0063794 및 GST-Akt1(0.5 μg) 또는 GST-S6K1(0.5 μg)이 존재하는 상태에서 0.1 mM ATP와 10 mM MgCl2를 첨가하여 시작합니다. 반응은 진동 플랫폼에서 30 °C로 30분 동안 수행하고 SDS 샘플 완충액을 첨가하여 중단합니다. 이후 반응 혼합물을 0.22-μm 공극 크기의 Spin-X 필터를 통해 여과하고, 샘플은 전기영동 및 해당 항체를 사용한 면역 블롯 분석을 거칩니다.

세포 분석:

[1]

  • 세포주

    Wild-type and mLST8 deficient MEFs

  • 농도

    Dissolved in DMSO, final concentration ~3 μM

  • 배양 시간

    24, 48, and 72 hours

  • 방법

    Cells are treated with KU-0063794 for 24, 48, and 72 hours, and the medium is changed every 24 hours with freshly dissolved this compound. For the measurement of cell growth, cells are washed once with PBS, and fixed in 4% (v/v) paraformaldehyde in PBS for 15 minutes. After washing once with water, the cells are stained with 0.1% Crystal Violet in 10% ethanol for 20 minutes and washed three times with water. Crystal Violet is extracted from cells with 0.5 mL of 10% (v/v) ethanoic (acetic) acid for 20 minutes. The eluate is then diluted 1:10 in water and absorbance at 590 nm is quantified. For the assessment of cell cycle distribution, cells are harvested by trypsinization, washed once in PBS, and re-suspended in ice-cold aq. 70% (v/v) ethanol. Cells are washed twice in PBS plus 1% (w/v) BSA and stained for 20 minutes in PBS plus 0.1% (v/v) Triton X-100 containing 50 g/mL propidium iodide and 50 g/mL RNase A. The DNA content of cells is determined using a FACSCalibur flow cytometer and CellQuest software. Red fluorescence (585 nm) is acquired on a linear scale, and pulse width analysis is used to exclude doublets. Cell-cycle distribution is determined using FlowJo software.

동물 연구:

[2]

  • 동물 모델

    Nu/Nu nude mice

  • 용량

    8 mg/kg

  • 투여

    i.p.

참조

  • https://pubmed.ncbi.nlm.nih.gov/19402821/
  • https://pubmed.ncbi.nlm.nih.gov/23349989/

고객 제품 검증

Effects of PI3K and mTOR inhibitors on IGF1R and AKT signaling in RMS cells. Rh41 cells were treated with 0.3 uM PI3K inhibitor BKM120, 0.3 uM mTOR inhibitor KU0063794 for the indicated time. Lysates were made and analyzed for p-AKT, S6RP and IGF1R.

데이터 출처 [ Oncogene , 2013 , 10.1038/onc.2013.509 ]

<p> </p><p>mTORC2 is required for mechanical activation of Akt. A, immunoblots of mdMSC subjected to strain for 45 min following treatment with the mTOR inhibitor KU0063794 (2uM). B, densitometric analysis of phosphorylated GSK3 (Ser-9) normalized to total GSK3. D, immunoblots of mdMSC treated with KU0063794 and then stimulated with insulin (50 nM) for 60 min.</p>

데이터 출처 [ J Biol Chem , 2011 , 286, 39450-6 ]

<p>mTORC2-mediated stretch-induced SGK-1 phosphorylation. SMCs infected with Ad-SGK-1 were pretreated with PPP (10 μmol/L), rapamycin (100 nmol/L),or Ku-0063794 (10 μmol/L) for 30 minutes and then were subjected to stretch or IGF-1 (10 ng/mL) for 30 minutes.</p><div><div> </div></div><p> </p>

데이터 출처 [ Circ Res , 2010 , 107, 1265-1274 ]

<p>For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of KU-0063794 by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 μM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.</p><div><div> </div></div><p> </p>

, , Dr. Yong-Weon Yi from Georgetown University Medical Center

Selleck's KU-0063794 인용됨 84 출판물

SLAP controls mTORC2 integrity via UBE3C-mediated non-degradative mLST8 ubiquitination to suppress colorectal tumorigenesis [ Cell Death Differ, 2026, 33(5):1020-1035] PubMed: 41398047
Molecular control of PDPNhi macrophage subset induction by ADAP as a host defense in sepsis [ JCI Insight, 2025, e186456] PubMed: 39903516
mTORC2-driven chromatin cGAS mediates chemoresistance through epigenetic reprogramming in colorectal cancer [ Nat Cell Biol, 2024, 10.1038/s41556-024-01473-0] PubMed: 39080411
Exploitation of the fibrinolytic system by B-cell acute lymphoblastic leukemia and its therapeutic targeting [ Nat Commun, 2024, 15(1):10059] PubMed: 39567540
mTORC1 regulates cell survival under glucose starvation through 4EBP1/2-mediated translational reprogramming of fatty acid metabolism [ Nat Commun, 2024, 15(1):4083] PubMed: 38744825
Resistin secreted by porcine alveolar macrophages leads to endothelial cell dysfunction during Haemophilus parasuis infection [ Virulence, 2023, 14(1):2171636] PubMed: 36694280
Mechanosensitive mTORC2 independently coordinates leading and trailing edge polarity programs during neutrophil migration [ Mol Biol Cell, 2023, 34(5):ar35] PubMed: 36857159
Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma [ Melanoma Res, 2023, 10.1097/CMR.0000000000000911] PubMed: 37467061
Targeting the REF1/STAT3 axis to treat tuberous sclerosis [ Cardiff University, 2023, ] PubMed: None
Aggresome assembly at the centrosome is driven by CP110-CEP97-CEP290 and centriolar satellites [ Nat Cell Biol, 2022, 24(4):483-496] PubMed: 35411088

반품 정책
Selleck Chemical의 무조건 반품 정책은 고객에게 원활한 온라인 쇼핑 경험을 보장합니다. 구매에 어떤 식으로든 불만족하시면, 수령일로부터 7일 이내에 모든 품목을 반품하실 수 있습니다. 제품 품질 문제(프로토콜 관련 문제 또는 제품 관련 문제)가 발생하는 경우, 원래 구매일로부터 365일 이내에 모든 품목을 반품하실 수 있습니다. 제품 반품 시 아래 지침을 따르십시오.

배송 및 보관
Selleck 제품은 실온에서 운송됩니다. 실온에서 제품을 받으셨더라도 안심하십시오. Selleck 품질 검사 부서에서 한 달간의 상온 보관이 분말 제품의 생물학적 활성에 영향을 미치지 않음을 확인하는 실험을 수행했습니다. 수령 후, 데이터시트에 설명된 요구 사항에 따라 제품을 보관하십시오. 대부분의 Selleck 제품은 권장 조건에서 안정적입니다.

인간, 수의학 진단 또는 치료 용도로 사용하지 마십시오.